Clearside Biomedical, Inc.
CLSD
$3.70
-$0.39-9.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.81% | 30.09% | -51.20% | 17.03% | 16.60% |
| Total Depreciation and Amortization | 90.91% | 203.57% | 295.00% | 368.75% | 175.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.14% | -35.80% | -50.76% | -16.64% | -57.29% |
| Change in Net Operating Assets | -570.02% | 18.61% | -82.73% | -165.38% | 10.35% |
| Cash from Operations | 16.74% | 25.74% | -1,161.41% | 2.67% | -6.39% |
| Capital Expenditure | 100.00% | 84.21% | -270.00% | 88.09% | 61.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 84.21% | 7,855.83% | 448.09% | -942.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -96.88% | 179.81% | -95.58% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -103.86% | 908.95% | -95.58% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 75.16% | -199.33% | 5,096.61% | 29.87% | -166.87% |